Daratumumab Intravenous and Insulin aspart, recombinant Subcutaneous
Determining the interaction of Daratumumab Intravenous and Insulin aspart, recombinant Subcutaneous and the possibility of their joint administration.
No interaction was detected between the selected drugs or effects of joint drug administration are currently understudied, and it takes time and accumulated statistics to determine their interaction. A doctor should be consulted to address the issue of joint drug administration.
Generic Name: daratumumab
Brand name: Darzalex
Synonyms: Daratumumab
Generic Name: insulin aspart
Brand name: Fiasp, NovoLog, NovoLog FlexPen, NovoLog PenFill, NovoLOG FlexTouch, Fiasp PenFill, Fiasp FlexTouch
Synonyms: Insulin aspart, Insulin Aspart
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Daratumumab Intravenous-Insulin degludec
- Daratumumab Intravenous-Insulin Degludec (U-100) Prefilled Pens
- Daratumumab Intravenous-Insulin Degludec (U-100) Vials
- Daratumumab Intravenous-Insulin Degludec (U-200) Prefilled Pens
- Daratumumab Intravenous-Insulin degludec and liraglutide
- Daratumumab Intravenous-Insulin degludec and liraglutide Subcutaneous
- Insulin aspart, recombinant Subcutaneous-Darbepoetin alfa
- Insulin aspart, recombinant Subcutaneous-Darbepoetin alfa Injection
- Insulin aspart, recombinant Subcutaneous-Darbepoetin Alfa Prefilled Syringes
- Insulin aspart, recombinant Subcutaneous-Darbepoetin Alfa Vials
- Insulin aspart, recombinant Subcutaneous-Darcalma
- Insulin aspart, recombinant Subcutaneous-Darifenacin